Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

被引:11
|
作者
Feng, Zengyu [1 ,2 ,3 ]
Li, Kexian [1 ,2 ]
Wu, Yulian [3 ]
Peng, Chenghong [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Pancreat Dis Ctr,Dept Gen Surg, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Res Inst Pancreat Dis, Shanghai, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Gen Surg, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
DCBLD2; pancreatic ductal adenocarcinoma; prognosis; diagnosis; extracellular vesicles; immune infiltrates; GENE-EXPRESSION; UP-REGULATION; STEM-CELLS; CANCER; ESDN; PROGRESSION;
D O I
10.3389/fmolb.2021.659168
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Accumulating evidence shows that the elevated expression of DCBLD2 (discoidin, CUB and LCCL domain-containing protein 2) is associated with unfavorable prognosis of various cancers. However, the correlation of DCBLD2 expression value with the diagnosis and prognosis of pancreatic ductal adenocarcinoma (PDAC) has not yet been elucidated. Methods: Univariate Cox regression analysis was used to screen robust survival-related genes. Expression pattern of selected genes was investigated in PDAC tissues and normal tissues from multiple cohorts. Kaplan-Meier (K-M) survival curves, ROC curves and calibration curves were employed to assess prognostic performance. The relationship between DCBLD2 expression and immune cell infiltrates was conducted by CIBERSORT software. Biological processes and KEGG pathway enrichment analyses were adopted to clarify the potential function of DCBLD2 in PDAC. Results: Univariate analysis, K-M survival curves and calibration curves indicated that DCBLD2 was a robust prognostic factor for PDAC with cross-cohort compatibility. Upregulation of DCBLD2 was observed in dissected PDAC tissues as well as extracellular vesicles from both plasma and serum samples of PDAC patients. Both DCBLD2 expression in tissue and extracellular vesicles had significant diagnostic value. Besides, DCBLD2 expression was correlated with infiltrating level of CD8(+) T cells and macrophage M2 cells. Functional enrichment revealed that DCBLD2 might be involved in cell motility, angiogenesis, and cancer-associated pathways. Conclusion: Our study systematically analyzed the potential diagnostic, prognostic and therapeutic value of DCBLD2 in PDAC. All the findings indicated that DCBLD2 might play a considerably oncogenic role in PDAC with diagnostic, prognostic and therapeutic potential. These preliminary results of bioinformatics analyses need to be further validated in more prospective studies.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma
    Bauden, Monika
    Kristl, Theresa
    Sasor, Agata
    Andersson, Bodil
    Marko-Varga, Gyorgy
    Andersson, Roland
    Ansari, Daniel
    BMC CANCER, 2017, 17
  • [22] Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma
    Monika Bauden
    Theresa Kristl
    Agata Sasor
    Bodil Andersson
    György Marko-Varga
    Roland Andersson
    Daniel Ansari
    BMC Cancer, 17
  • [23] DCBLD2 is a novel biomarker candidate of myxofibrosarcoma invasion identified by proteomics
    Kikuta, Kazutaka
    Kubota, Daisuke
    Yoshida, Akihiko
    Morioka, Hideo
    Nakamura, Masaya
    Matsumoto, Morio
    Chuman, Hirokazu
    Kawai, Akira
    Kondo, Tadashi
    CANCER SCIENCE, 2018, 109 : 716 - 716
  • [24] Genomewide transcriptomic profiling identifies a novel miRNA signature for predicting lymph node metastasis in patients with pancreatic ductal adenocarcinoma
    Nishiwada, Satoshi
    Yamamura, Kensuke
    Kandimalla, Raju
    Akahori, Takahiro
    Nakamura, Kota
    Baba, Hideo
    Sho, Masayuki
    Goel, Ajay
    CANCER RESEARCH, 2019, 79 (13)
  • [25] Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling
    Guo, Xin
    Lv, Xiaohui
    Fang, Cheng
    Lv, Xing
    Wang, Fengsong
    Wang, Dongmei
    Zhao, Jun
    Ma, Yueyun
    Xue, Yu
    Bai, Quan
    Yao, Xuebiao
    Chen, Yong
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (08) : 1821 - 1829
  • [26] Plasma COL10A1 Level, a Potential Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma
    Wang, Tianlei
    Bao, Xinrui
    Yang, Fang
    Pan, Shenbin
    Xu, Ke
    Ren, Tao
    ONCOTARGETS AND THERAPY, 2024, 17 : 949 - 959
  • [27] Candidate diagnostic and prognostic markers for pancreatitis and pancreatic ductal adenocarcinoma
    Wilkie, Thomas M.
    Kantheti, Havish
    FASEB JOURNAL, 2022, 36
  • [28] A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma
    Stosic, Kosta
    Senar, Oier Azurmendi
    Tarfouss, Jawad
    Bouchart, Christelle
    Navez, Julie
    Van Laethem, Jean-Luc
    Arsenijevic, Tatjana
    CELLS, 2024, 13 (01)
  • [29] Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma
    Penheiter, Alan R.
    Erdogan, Sibel
    Murphy, Stephen J.
    Hart, Steven N.
    Lima, Joema Felipe
    Rohakhtar, Fariborz Rakhshan
    O'Brien, Daniel R.
    Bamlet, William R.
    Wuertz, Ryan E.
    Smyrk, Thomas C.
    Couch, Fergus J.
    Vasmatzis, George
    Bender, Claire E.
    Carlson, Stephanie K.
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [30] Keratin 17 is a negative prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
    Oblein, Lyanne
    Roa-Pena, Lucia
    Babu, Sruthi
    Allard, Felicia D.
    Marchenko, Natalia D.
    Escobar-Hoyos, Luisa F.
    Shroyer, Kenneth R.
    CANCER RESEARCH, 2022, 82 (22) : 27 - 28